# Biocon (NSE: BIOCON) share price, financials and shareholding Source: https://app.pivotnow.in/stock/BIOCON · Pivot · prices to 22 Oct 2026 Biocon (NSE: BIOCON) closed at ₹330.00 on 22 Oct 2026, down 1.05% on the day. With a market capitalisation of ₹53,780 Cr, it ranks 187th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology. At its last close the stock traded at 116.6× trailing earnings, against a return on equity of 1.1% in FY26. Over the past year the share price has fallen 5.9%. Its 52-week range is ₹328.35 (22 Oct 2026) to ₹447.15 (16 Jul 2026); the last close is 26.2% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹4,292 Cr (+9.8% year on year) and net profit ₹137 Cr (+53.4%), on a consolidated basis. Promoters held 44.68% of the company as of 30 Jun 2026. ## Key numbers | Metric | Value | | --- | --- | | Last close | ₹330.00 | | Market cap | ₹53,780 Cr | | P/E (trailing) | 116.6 | | ROE | 1.1% (FY26) | | ROCE | 3.7% (FY26) | | Debt to equity | 0.44 | | 52-week high | ₹447.15 (16 Jul 2026) | | 52-week low | ₹328.35 (22 Oct 2026) | | 1-year return | −5.9% | ## Quarterly results (₹ crore, consolidated) | Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) | | --- | --- | --- | --- | --- | --- | | Q1 FY27 | ₹4,292 Cr | +9.8% | ₹137 Cr | +53.4% | ₹0.87 | | Q4 FY26 | ₹4,484 Cr | +2.9% | ₹199 Cr | −56.8% | ₹0.79 | | Q3 FY26 | ₹4,123 Cr | +9.3% | −₹52 Cr | −163.9% | ₹1.08 | | Q2 FY26 | ₹4,263 Cr | +18.7% | ₹133 Cr | +390.0% | ₹0.66 | | Q1 FY26 | ₹3,910 Cr | +13.9% | ₹89 Cr | −89.6% | ₹0.26 | | Q4 FY25 | ₹4,358 Cr | +12.8% | ₹459 Cr | +103.6% | ₹2.88 | | Q3 FY25 | ₹3,773 Cr | +6.3% | ₹81 Cr | −89.6% | ₹0.21 | | Q2 FY25 | ₹3,590 Cr | +3.7% | ₹27 Cr | −86.2% | −₹0.13 | ## Annual results (₹ crore) | Fiscal year | Revenue | Net profit | | --- | --- | --- | | FY25 | ₹15,262 Cr | ₹1,429 Cr | | FY24 | ₹14,756 Cr | ₹1,382 Cr | | FY23 | ₹11,174 Cr | ₹810 Cr | | FY22 | ₹8,184 Cr | ₹979 Cr | | FY21 | ₹7,106 Cr | ₹916 Cr | | FY20 | ₹6,301 Cr | ₹871 Cr | ## Shareholding (30 Jun 2026) - Promoters: 44.68% - Foreign institutions: 8.14% - Domestic institutions: 23.38% - Non-institutions: 23.75% ## Peers | Company | Price | Market cap | P/E | ROE | | --- | --- | --- | --- | --- | | [Alkem Laboratories](https://app.pivotnow.in/stock/ALKEM) | ₹4,970.00 | ₹59,424 Cr | 25.8 | 16.6% | | [Aster DM Health](https://app.pivotnow.in/stock/ASTERDM) | ₹655.00 | ₹57,095 Cr | 102.3 | 8.5% | | [Fortis Healthcare](https://app.pivotnow.in/stock/FORTIS) | ₹724.00 | ₹54,659 Cr | 52.6 | 10.5% | | [Abbott India](https://app.pivotnow.in/stock/ABBOTINDIA) | ₹25,340.00 | ₹53,846 Cr | 34.7 | 33.4% | | [IPCA Laboratories](https://app.pivotnow.in/stock/IPCALAB) | ₹1,899.80 | ₹48,199 Cr | 42.3 | 14.2% | | [Gland Pharma](https://app.pivotnow.in/stock/GLAND) | ₹2,850.00 | ₹47,014 Cr | 45.7 | 9.9% | ## Questions and answers ### What is the share price of Biocon today? Biocon (NSE: BIOCON) last closed at ₹330.00 on 22 Oct 2026. Its 52-week high is ₹447.15 and its 52-week low is ₹328.35. ### What is the market cap of Biocon? Biocon's market capitalisation is ₹53,780 Cr (₹53,780 Cr) at the 22 Oct 2026 close, ranking 187th among the NSE companies Pivot tracks. ### What is the P/E ratio of Biocon? Biocon trades at a trailing P/E of 116.6. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 45.7. ### What is the ROE and ROCE of Biocon? Return on equity was 1.1% in FY26 and return on capital employed was 3.7% in FY26 (consolidated figures). ### Is Biocon a debt-free company? No. Biocon's debt-to-equity ratio was 0.44 in FY26, with total debt of ₹10,746 Cr. ### What were Biocon's latest quarterly results? For Q1 FY27 (quarter ended 30 Jun 2026), Biocon reported revenue of ₹4,292 Cr, +9.8% year on year, and net profit of ₹137 Cr, +53.4% year on year. ### How has Biocon stock performed over the last year? Biocon's share price has fallen 5.9% over the past year, −24.8% over three months and −16.5% over one month, to the 22 Oct 2026 close. ### What is the shareholding pattern of Biocon? As of 30 Jun 2026: promoters 44.68%, foreign institutions 8.14%, domestic institutions 23.38%, non-institutions 23.75%. ### Who are Biocon's competitors? The listed Pharma & Healthcare companies closest to Biocon by market cap are Alkem Laboratories, Aster DM Health, Fortis Healthcare, Abbott India, IPCA Laboratories and Gland Pharma. ### Is Biocon a good stock to buy? Pivot does not give buy or sell recommendations. This page sets out Biocon's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BIOCON against its own history before risking money. This is analysis, not financial advice. --- Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.